Amylin Phase III exenatide data

AMLN and partner Eli Lilly (LLY) said exenatide synthetic exendin-4 met the primary endpoint of a reduction in glucose levels

Read the full 207 word article

How to gain access

Continue reading with a
two-week free trial.